The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.

@article{Wu2014TheCE,
  title={The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.},
  author={S Wu and F Sun and Y Zhang and Z Yang and Tianpei Hong and Y-c Chen and Siyan Zhan},
  journal={Journal of clinical pharmacy and therapeutics},
  year={2014},
  volume={39 1},
  pages={7-13}
}
WHAT IS KNOWN AND OBJECTIVE Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antidiabetic drugs. Their wider use for the treatment of patients with type 2 diabetes mellitus has led to concerns about its cardiovascular effects. However, the robustness of data leading to those concerns is unclear. The purpose of this study is to systematically assess the robustness of the available evidence on the adverse cardiovascular effects of GLP-1 receptor agonists in patients with type… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…